Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Motor Neurone Disease Association

- PMLiVE

AbbVie takes anti-tau drug into phase II for Alzheimer’s

Also testing antibody in rare condition PSP, for which FDA has awarded fast-track designation

Bayer symbol

Bayer helps bankroll new stem cell company BlueRock

Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies

PatientsLikeMe launches ‘virtual trial’ in ALS

Partners with The Duke ALS Clinic on study of the Soy Peptide Lunasin

- PMLiVE

Charity coalition pledges millions for brain disease research

Will invest £30m developing candidates for neurodegenerative conditions

- PMLiVE

AbbVie-partnered Calico unveils first licensing deal

Google’s healthcare research business gains rights to drug prospects in neurodegeneration

Biogen Idec building

Biogen Idec signs brain research deal with Edinburgh University

Will identify potential treatments for multiple sclerosis and motor neurone disease

- PMLiVE

Upcoming treatments for amyotrophic lateral sclerosis

While some progress has been made in the treatment of ALS, combination therapies with drugs that target other pathways, alongside stem cell technology, are sorely needed

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links